Renal (25 companies · 15 conditions)

Conditions

Lupus Nephritis 11 Rare Immunoglobulin A Nephropathy 8 Rare Chronic Kidney Disease 6 Focal Segmental Glomerulosclerosis 4 Rare Membranous Nephropathy 4 Rare Hyperphosphatemia 2 Minimal Change Disease 2 Rare Polycystic Kidney Disease 2 Rare Acute Kidney Injury 1 Alport Syndrome 1 Rare APOL1-Mediated Kidney Disease 1 Rare C3 Glomerulopathy 1 Rare Cystinuria 1 Rare Delayed Graft Function 1 Diabetes Insipidus 1 Rare

Companies

Ticker	Company	Therapeutic areas	In Renal	Lead stage	Mkt cap	Programs
ACET	Adicet Bio	ImmunologyNeurology+2 Rare	1	Phase 1	$28.6M	8
AKBA	Akebia Therapeutics	HematologyOphthalmology+2 Rare	7	Approved	$111M	10
ANNX	Annexon	HematologyNeurology+2 Rare	1	Phase 3	$796M	6
ARDX	Ardelyx	GI/HepatologyRenal	1	Approved	$724M	4
AUTL	Autolus Therapeutics	HematologyImmunology+3 Rare	1	Approved	$341M	12
CABA	Cabaletta Bio	DermatologyImmunology+2 Rare	1	Phase 2	$280M	8
IPSC	Century Therapeutics	ImmunologyMetabolic+1 Rare	2	Phase 1	$304M	9
CLYM	Climb Bio	HematologyImmunology+1 Rare	3	Phase 2	$604M	8
CGEM	Cullinan Therapeutics	HematologyImmunology+2 Rare	1	NDA Submitted	$728M	10
IRON	Disc Medicine	GI/HepatologyHematology+2 Rare	1	Phase 3	$3.59B	9
ELOX	Eloxx Pharmaceuticals	DermatologyRenal Rare	2	Phase 2	$50.2M	4
ETON	Eton Pharmaceuticals	GI/HepatologyInfectious Disease+3 Rare	1	Approved	$1.63B	17
FATE	Fate Therapeutics	ImmunologyOncology+1 Rare	1	Phase 2	$224M	10
IONS	Ionis Pharmaceuticals	CardiovascularHematology+5 Rare	2	Approved	$6.55B	29
JBIO	Jade Biosciences	ImmunologyRenal Rare	1	Phase 2	$958M	4
KYTX	Kyverna Therapeutics	ImmunologyNeurology+1 Rare	1	NDA Submitted	$302M	7
MAZE	Maze Therapeutics	MetabolicRenal Rare	2	Phase 2	$1.90B	4
MLYS	Mineralys Therapeutics	CardiovascularRenal+1	1	NDA Submitted	$1.36B	3
NKTX	Nkarta	ImmunologyNeurology+1 Rare	2	Phase 1	$124M	8
NVCT	Nuvectis Pharma	HematologyOncology+1 Rare	2	Phase 3	$719M	9
PCSA	Processa Pharmaceuticals	GI/HepatologyImmunology+2 Rare	2	Phase 2	$5.4M	7
SCYX	Scynexis	Infectious DiseaseRenal Rare	1	Approved	$34.8M	5
TVTX	Travere Therapeutics	MetabolicRenal Rare	6	Approved	$4.76B	7
UNCY	Unicycive Therapeutics	Renal	2	NDA Submitted	$98.9M	2
VERA	Vera Therapeutics	Infectious DiseaseRenal Rare	4	Approved	$2.15B	6